¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple overlapping thin slab acquisition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
  • multiple excitation
    ´Ù¹ßÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
  • multiple field irradiation
    ´ÙÁ¶»ç¿µ¿ªÁ¶»ç
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±ÙÀ°¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • slice acquisition
    ÀýÆí ȹµæ
  • slice interleaved acquisition
    ÀýÆí »ðÀÔ È¹µæ
  • stimulated echo acquisition mode (STEAM)
    ÀÚ±Ø ¿¡ÄÚ È¹µæ¹æ½Ä
  • volume acquisition
    ¿ëÀû ȹµæ
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ¼±Á¾ ÁõÈıº(ÝÂìÆàõÒýÛ¡Ò®ÝÂù²àÍðþñøý¦ÏØ).
  • exostosis,hereditary multiple
    ´Ù¹ß¼º À¯Àü¼º
  • familial multiple lipomatosis
    °¡Á·¼º ´Ù¹ß¼º Áö¹æÁ¾Áõ
  • infection, multiple
    ´ÙÁß°¨¿°, º¹¼ö±Õ°¨¿°
  • infectious multiple gangrene of skin
    Àü¿°¼º ÇǺΠ´Ù¹ß¼º ±«Àú
  • least common multiple =LCM
    ÃÖ¼Ò°ø¹è¼ö(ÊÙË­ËÑËà).
  • multiple
    ´Ù¹ß¼ºÀÇ,´Ù¼öÀÇ,´Ù¾çÇÑ
  • multiple
    ´Ù¹ßÀÇ
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË).
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË)
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(´Ù¹ß¼º³ó¾ç).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multi echo stimulated echo acquisition
    ´ÙÁß¿¡ÄÚÀڱؿ¡ÄÚȸµæ
  • multislice imaging acquisition
    ´ÙÁß¹ÚÆí¿µ»óȹµæ
  • number of acquisition
    ȹµæÈ¸¼ö
  • rapid acquisition with relaxation enhancement [=RARE]
    ÀÌ¿ÏÁõ°­±Þ¼Óȹµæ
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • sequential multislice acquisition
    ¼øÂ÷Àû´ÙÀýÆíȹµæ
  • slice acquisition
    ÀýÆíȹµæ
  • slice interleaved acquisition
    ÀýÆí»ðÀÔȹµæ
  • stimulated echo acquisition mode [=STEAM]
    Àڱؿ¡ÄÚȹµæ¹æ½Ä
  • volume acquisition
    ¿ëÀûȹµæ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TLC tender loving care; thin-layer chromatography; total L-chain concentration; total lung capacity; tot...
TLE temporal lobe epilepsy; thin-layer electrophoresis; total lipid extract
TMN thin membrane nephropathy
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TBMD Thin basement membrane disease
TLC Thin layer chromatographic
TIA Thin layer immunoassay
ATL ascending thin limb
TLC thin layer
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º °ñ´Ü ÀÌÇü¼ºÁõ
  • multiple epulides fissurata
    ´Ù¹ß¼º ¿­¼º Ä¡À°Á¾
  • multiple excitaiton
    ´ÙÁß ¿©±â
  • multiple factor
    ´Ù¹ß¼º ÀÎÀÚ
  • multiple fracture
    ´Ù¹ß¼º °ñÀý
  • multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
    ´Ù¹ß¼ºÀÌ¸ç ¸ð¹Ý ¸ð¾çÀÎ ¿Ü¹è¿±¼º, Á߹迱¼º ¹× ³»¹è¿±¼ºÀÇ ½Å»ý¹°¼º ±âÇüÀ» Ư¡À¸·Î ÇÏ´Â À¯Àüº´. ¾ó±¼ ¹× ±¸°­ Á¡¸·ÀÇ ±¸ÁøÀÌ °¡Àå Æ¯Â¡ÀûÀÎ º´º¯ÀÌ´Ù. ±× ¿ÜÀÇ º´º¯Àº ÇǺÎ, °©»ó¼±
  • multiple handicapped children
    º¹ÇÕ Àå¾Ö¾Æ
  • multiple infection
    ´Ù¹ß¼º °¨¿°
  • multiple lentigines syndrome
    ´Ù¹ß¼º ÈæÀÚ ÁõÈıº
    »ó¿°»öü¼º ¿ì¼ºÀÇ À¯Àü¼º ÁõÈıºÀ¸·Î¼­ ´Ù¹ß¼º °ËÀº »ç¸¶±Í, ¹«ÁõÈıº¼º ½ÉÀå °áÇÔ. ƯÀÌÇÑ ¾ó±¼ ¸ð¾ç, Æóµ¿¸Æ ÇùÂø, Áö°¢ ½Å°æ¼º ³­Ã», °ñ°Ý ÀÌ»ó, ¾ç¾È °Ý¸®, ¼º±â ±âÇü µîÀ» ³ªÅ¸³½´Ù.
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾, ´Ù¹ß¼º ÇüÁú ¼¼Æ÷Á¾
    1. °ñ¼öÀÇ ¾Ç¼º ½Å»ý¹°. 2. ÇüÁú ¼¼Æ÷ Áúȯ±º Áß °¡Àå Áß¿äÇϰí ÈçÇÑ ÇüÅ·μ­ °ñ°Ý°è¿Í ¶§·Î ¿¬°ñ ºÎÀ§¿¡ ¼º¼÷ ¶Ç´Â ¹Ì¼º¼÷ ÇüÁú ¼¼Æ÷µéÀÌ ´Ù¹ß¼º Á¾±â¸¦ Çü¼ºÇÏ´Â °æ¿ìÀÌ´Ù. 3. ´Ù¹ß¼º °ñ¼öÁ¾Àº ³­Ä¡¼º ¾Ç¼º Ç÷¾× Á¾¾çÀÌ´Ù. ´Ù¸¥ Á¾¾çµé°ú ¸¶Âù°¡Áö·Î ¿øÀÎÀº ¸ð¸£¸ç ÁÖ¿ä Áõ»óÀ¸·Î´Â »ÀÀÇ ¾àÈ­, °ñÀý µîÀÌ °¡Àå ÈçÇϰí, ºóÇ÷, ½Å ºÎÀü, °¨¿° µîÀ¸·Î ³ªÅ¸³­´Ù. º´±â´Â 1, 2, 3±â·Î ³ª´©¸ç ´ë°³ 3±â¿¡ ÁÖ·Î ¹ß°ßµÇ³ª ±Ù·¡¿¡´Â °Ç°­ Áø´Ü µîÀ» ÅëÇØ Á¶±â¿¡ ¹ß°ßµÇ±âµµ ÇÑ´Ù. ´ëÁõÀûÀÎ Ä¡·á°¡ Áß¿äÇϸç Áúȯ ÀÚü¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·áÀÇ ¼ºÀûÀº ¸¸Á·½º·´Áö ¾Ê´Ù. Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº °æ¿ì´Â Æò±Õ ¼ö¸íÀÌ ¼ö°³¿ù¿¡ ºÒ°úÇϰí Ä¡·áÇÑ °æ¿ìÀÇ Æò±Õ ¼ö¸íÀº 3³â Á¤µµÀ̳ª 3±â¿¡¼­´Â 1³â ³»¿ÜÀÌ´Ù. 1990³â´ë¿¡ Ä¡·á ¹æ¹ýÀÌ ¹ß´ÞÇÏ¿© ÀÎÅÍÆä·Ð°ú °ñ¼ö À̽ÄÀÌ ¼Ò°³µÇ¾ú´Ù. ÀÎÅÍÆä·ÐÀº ȯÀÚÀÇ º´ÀÌ ¸¹ÀÌ °¨¼ÒÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÑ °æ¿ì Àç¹ßÀ» ´ÊÃß´Â È¿°ú°¡ °ËÁõµÇ¾ú´Ù. ȯÀÚÀÇ °ñ¼ö, ȤÀº ±ÙÀÚ¿¡´Â ¸»ÃÊÇ÷¾×ÀÇ Á¶Ç÷¸ð¼¼Æ÷¸¦ À̽ÄÇÏ°í °í¿ë·®ÀÇ Ç×¾Ï Ä¡·á¸¦ ÇÏ´Â ÀÚ°¡ ÀÌ½Ä Ä¡·á´Â ÇöÀç±îÁö Æò±Õ ¼ö¸íÀÌ 5³âÀÌ »óÀ¸·Î º¸°íµÇ¾î °ú°ÅÀÇ Ä¡·á¹ý°ú´Â ¿ùµîÇÑ Çâ»óÀ» º¸¿© Ȱ¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â ÀÚ°¡ À̽Ŀ¡¼­µµ ¾Ï ¼¼Æ÷°¡ ¾ø´Â Á¶Ç÷¸ð¼¼Æ÷¸¸À» ÃßÃâÇÏ¿© À̽ÄÇϴ ÷´ÜÀÇ Ä¡·á¹ýÀÌ ¼Ò°³µÇ°í ÀÖ¾î ¿ÏÄ¡¸¦ ÇâÇØ ÇÑ °ÉÀ½¾¿ ÁøÇàµÇ°í ÀÖ´Ù°í º¸¿©Áø´Ù. ´Ù¹ß¼º °ñ¼öÁ¾ÀÇ Áø´ÜÀº Southwest Oncology Grou
  • multiple myositis
    ´Ù¹ß ±Ù¿°, ´Ù¹ß¼º ±Ù¿°
  • multiple neurofibromatosis
    ´Ù¹ß ½Å°æ ¼¶À¯Á¾Áõ
  • multiple neuroma syndrome
    ´Ù¹ß¼º ½Å°æÁ¾ ÁõÈıº
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á